Navigation Links
Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma
Date:3/2/2009

BERKELEY, Calif., March 2 /PRNewswire/ -- Aerovance Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial(TM), of inhaled dry powder Aerovant in patients with uncontrolled asthma.

Study initiation begins today in the United States for AeroTrial, a double-blind, randomized, placebo-controlled, Phase IIb dose-ranging study. Aerovance expects to enroll approximately 500 patients with moderate to severe asthma, in the United States and Europe, who are poorly controlled by the combination of inhaled corticosteroids (ICS) and long-acting beta agonists (LABA). Patients will be randomly assigned to receive one of three Aerovant doses (1 mg, 3 mg or 10 mg) or placebo by inhalation twice daily for 12 weeks, during which time their standard ICS and LABA therapies will be gradually withdrawn. The primary endpoint is exacerbation incidence on Aerovant therapy as compared to placebo. Secondary endpoints include pulmonary function, time to exacerbation, daily peak expiratory flow (PEF) and symptom scores, immunoglobulin E (IgE) levels, and fractional concentration of expired nitric oxide (FeNO).

"Regulatory clearance and initiation of AeroTrial are significant milestones for Aerovance and potentially for patients living with uncontrolled asthma. The efficacy and safety data from our completed Aerovant studies are promising, and we are pleased to begin evaluation of this compound in a large number of moderate to severe asthmatics," said Mark Perry, Aerovance's president and chief executive officer. "Aerovant targets a root cause of asthma by blocking the signaling activity of two key cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13), critical in the progression of the disease. Our Phase IIa data suggest that targeted delivery to the lung is superior
'/>"/>

SOURCE Aerovance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Show Aerovances Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014  PTC Therapeutics, Inc. (NASDAQ: ... it approved non-statutory stock options to purchase an aggregate ... new employees. The awards were made pursuant to the ... new hires, employment compensation. The inducement grants ... 2014 and are being made as an inducement material ...
(Date:8/1/2014)... 2014  With monumental health reform coming into effect, ... language. Clinical efficacy is no longer the sole driver ... like PCORI are directing roughly $1 billion a year ... and environments, the federal healthcare ecosystem is changing, and ... outcomes and managed markets to the right people in ...
(Date:8/1/2014)... LAVAL, Quebec and NEW YORK ... Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management, L.P. ... by Allergan, Inc. (NYSE: AGN ) in ... Pershing Square regarding the tender offer rules.  ... an attempt to interfere with shareholders, efforts to call ...
Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
... Reportlinker.com announces that a new market research ... Insulin- Western Europe ... package contains 14 insulin market analyses from ... Denmark, Finland, France, Germany, Ireland, Italy, the ...
... Calif., July 31, 2011 Accuray Incorporated ... radiation oncology company, announced today that it will showcase ... TomoTherapy® Radiation Therapy Treatment System in the ... Association of Physicists in Medicine (AAPM)/Canadian Organization of Medical ...
Cached Medicine Technology:Insulin- Western Europe 2Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 2Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 3Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 4
(Date:8/1/2014)... Although most people are aware of the need ... is particularly important for women. Changes to hormone levels ... ways. Hormones can affect the blood supply to the ... receive nutrients essential to fight infection. In addition, changing ... produced by plaque bacteria, increasing the risk of inflammation ...
(Date:8/1/2014)... 02, 2014 The successful development of ... business of Guangdong FODAY Automobile Co.,LTD. As early as ... had already organized an excellent team to develop a ... detailed, in-depth technical plans. The company’s vice president Liming ... the direct involvement of the specific arrangement and the ...
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... top bridesmaid dresses online. At the moment, all the ... 52% off. According to the company’s senior spokesman, the special ... The company’s stock is limited. Those who are thinking of ... soon as possible. All its products are delicately made by ...
(Date:8/1/2014)... August 01, 2014 Cannabis use among young ... aged 14 to 17 having used marijuana at least once ... their slogan “Say ‘No’ to Drugs, Say ‘Yes to Life,’ ... out to youth this summer with factual information about drugs, ... six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation (JPML) issued ... strokes, heart attacks, and other injuries in men who ... as the transferee judge and ordered what could be ... , As one of his first organizing acts, Judge ... who will move the litigation forward on behalf of ...
Breaking Medicine News(10 mins):Health News:Midtown Dentistry Renews Call for Women to Look After Their Dental Health 2Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2
... Dr. Hungerford is ... invasive single as well as double hip replacement procedures. , ... (Vocus) June 29, 2009 -- Noted orthopedic surgeon Marc ... hospital,s Medical Director of Joint Replacement and Reconstruction, Dr. Thomas Whitten, Chief of Orthopedics at ...
... the victims of these falls, CDC says , MONDAY, ... 47,000 elderly Americans are treated at hospital emergency departments ... according to a federal government study released Monday. , ... day. , U.S. Centers for Disease Control and Prevention ...
... the 1600s quinine was the first effective treatment in the ... commonly used treatment against this devastating disease. But the drug ... can range from sickness and headaches to blindness, deafness and ... knew why. Scientists at The University of Nottingham have ...
... emergency departments first sites for savings ... CalRHIO announced today that it has selected the RAND ... measure savings resulting from physicians having secure electronic access to ... The first phase of the initiative will measure savings in ...
... N.C., June 29 Carolinas HealthCare System ... growth and development of cardiovascular services in North and South ... Sanger Heart and Vascular Institute (SHVI) represents a ... and Vascular Institute. The Institute will continue serving as a ...
... Medicaid Funding Boost Merely Scratches Surface in Terms of Meeting ... In summing up the 2009 session of the Texas ... by Governor Rick Perry, the Texas Health Care Association (THCA) ... ($60 million general revenue) for Medicaid-financed nursing home care, substantially ...
Cached Medicine News:Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 2Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 3Health News:47,000 Elderly Hurt in Walker, Cane Mishaps Each Year 2Health News:Breakthrough in combating the side effects of quinine 2Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 2Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 3Health News:Sanger Clinic Lends Its Name to New Heart Care Institute Serving NC and SC 2Health News:THCA on 2009 Legislative Session: Seniors' Medicaid-Financed Nursing Home Care Requires Substantially More Investment as Population Ages, Care Needs Grow 2
... For Excellent Drainage PLUS Greater Patient ... BLAKE Drains are white, radiopaque silicone drains ... a solid core center. Their other components ... extension tubing and an adapter. The drains ...
Used for percutaneous placement of laparoscopic surgical instruments. Check-Flo® valve provides a secure seal around the instruments to be introduced. Supplied sterile in peel-open packages. Inte...
Used for internal biliary drainage. Supplied sterile in peel-open packages. Intended for one-time use....
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: